Furthermore, while several SAC inhibitors that increase CIN show promising potential for reducing tumor growth and have already entered clinical trial phase, the success of such therapies depends on factors such as CIN status and the capacity of the tumor cells to tolerate CIN.267,427–437 Despite these challenges, recent advances suggest promising possibilities for a new, personalized, CIN-specific approach to anti-tumor therapy.358,406,410,411,423–426,438,451–455. The gene discussed is ADCY10; the disease is cervical squamous intraepithelial neoplasia.